The Biotechnology Innovation Organization (BIO) has called on Washington to adopt a comprehensive national biotechnology strategy, warning that China is rapidly closing the gap in an industry now deemed critical to economic competitiveness and national security. This month's appeal frames biotech as the next space race, a comparison that resonates as the United States and China vie for leadership across semiconductors, telecommunications, and artificial intelligence.
Chinese life-sciences companies are no longer just manufacturers or contract research providers. They are emerging as sources of intellectual property and novel drug development. BeOne's blood-cancer therapy Brukinsa generated US$3.9 billion in annual sales in 2025, while Akeso's cancer medicine ivonescimab has drawn international attention for its clinical performance. These firms illustrate a broader shift: Chinese companies now compete on drug discovery, not just cost.
According to BIO, Chinese biotechnology assets accounted for 56% of global licensing deal value in 2026, up from just 10% in 2021. Chinese companies generated approximately US$59 billion in licensing deal value, surpassing their US counterparts. Most analysis attributes this rise to industrial policy and state support, but another force may be equally important: demographics.
Demographics as an innovation signal
China's aging population is usually portrayed as a drag on growth. Its old-age dependency ratio recently exceeded its child dependency ratio for the first time, signaling a structural shift. Conventional wisdom suggests aging weakens competitiveness by reducing labor-force growth and increasing fiscal pressures. But that interpretation misses a crucial point: aging changes the structure of demand.
As societies age, healthcare becomes a larger share of economic activity. The need for cancer therapies, cardiovascular treatments, metabolic medicine, diagnostics, and preventive care grows. Problems once seen as niche medical challenges become mass-market opportunities. In this light, demographics function as an innovation signal, identifying where future healthcare needs will concentrate and where capital and talent are likely to generate returns.
This dynamic is particularly relevant in life sciences because healthcare innovation differs from other high-priority industries. Semiconductor demand is influenced by technological adoption, and AI depends on digital transformation. In life sciences, demographic reality is a growth driver. The older a society becomes, the more valuable technologies that help people stay healthier for longer become. China's aging population may be creating conditions that accelerate healthcare innovation even as it weighs on other parts of the economy.
The commercial success of GLP-1 medicines offers a useful example. Novo Nordisk and Eli Lilly benefited from growing recognition that metabolic disease is one of the largest healthcare challenges facing developed economies. The result was a vast market driven by an identifiable health burden. China's demographic transition creates similar incentives across a wider range of therapeutic areas, from oncology to age-related diseases.
Chinese drug developers are responding accordingly. BeOne's global oncology expansion and Akeso's advances in cancer immunotherapy demonstrate how demographic pressures can reinforce scientific ambition. These firms are responding to demographic necessity and the commercial opportunities it creates.
This dynamic may also explain why biotechnology is moving higher on geopolitical agendas. For Washington, biotech has become a geopolitical competition; for Beijing, it is a tool of economic resilience. Both perspectives point to the same conclusion: the life-sciences sector is no longer merely a healthcare industry—it is becoming a core national capability.
The comparison with the space race is revealing. The Cold War space race was a contest for technological leadership and industrial capacity. Today's biotech race reflects similar ambitions, but geopolitics and demographics are shaping this competition. In the coming decades, aging populations are likely to become one of the most powerful forces directing capital and research investment, giving China a paradoxical advantage.
The demographic transition, often cited as one of China's greatest economic challenges, may also be helping create one of its most important growth industries. As the country's export boom masks deeper domestic weaknesses, biotech offers a path to resilience. The biotechnology race is frequently portrayed as a contest between the United States and China, but a deeper reality sits underneath: demographics may prove as important to biotechnology as data is to artificial intelligence. China's aging population is often viewed as a liability—it may also become one of the country's most powerful engines of innovation.
